Teriparatide
- Generic Name
- Teriparatide
- Brand Names
- Forsteo, Forteo, Movymia, Kauliv, Sondelbay, Teriparatide Sun, Terrosa, Livogiva
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 52232-67-4
- Unique Ingredient Identifier
- 10T9CSU89I
- Background
Teriparatide is a recombinant parathyroid hormone (PTH) analog and a potent osteoanabolic agent. It is made up of the first amino(N)-terminal 34 amino acids of the human PTH. First approved in the United States in November 2002 and in Europe in April 2003, teriparatide makes the first approved drug in a new category of osteoporosis therapy called anabolic th...
- Indication
Teriparatide is indicated:
- Associated Conditions
- Osteoporosis, Osteoporosis caused by Glucocorticoid Treatment, Primary Osteoporosis
- Associated Therapies
- -
The Forteo Alendronate Comparator Trial
- Conditions
- Interventions
- First Posted Date
- 2015-04-14
- Last Posted Date
- 2015-04-14
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 203
- Registration Number
- NCT02416271
- Locations
- 🇵🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Juan, Puerto Rico
A Study Aimed at Assessing the Pharmacokinetic Properties of RGB-10 and Forsteo
- First Posted Date
- 2014-08-22
- Last Posted Date
- 2015-03-18
- Lead Sponsor
- Gedeon Richter Plc.
- Registration Number
- NCT02223416
- Locations
- 🇬🇧
Celerion (UK), Belfast, United Kingdom
A Three Stage, Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of Oral PTH (1-34) in Healthy Subjects
- First Posted Date
- 2014-07-29
- Last Posted Date
- 2015-10-07
- Lead Sponsor
- Entera Bio Ltd.
- Target Recruit Count
- 42
- Registration Number
- NCT02202603
- Locations
- 🇮🇱
HMO Clinical Research Center Hadassah Ein Kerem Medical Center, Jerusalem, Israel
Denosumab and Teriparatide Study (DATA-HD and DATA-EX)
- Conditions
- Interventions
- First Posted Date
- 2014-06-27
- Last Posted Date
- 2021-02-09
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 76
- Registration Number
- NCT02176382
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Teriparatide for Fracture Repair in Humans
- Conditions
- Interventions
- First Posted Date
- 2014-03-19
- Last Posted Date
- 2015-09-17
- Lead Sponsor
- Medical University of Vienna
- Registration Number
- NCT02091492
- Locations
- 🇦🇹
Medical University Vienna; St. Vincent Hospital, Vienna, Austria
Does PTH 1-34 (Teriparatide) Enhance Spinal Fusion in Humans?
- First Posted Date
- 2014-03-18
- Last Posted Date
- 2019-04-17
- Lead Sponsor
- University Hospital, Linkoeping
- Target Recruit Count
- 34
- Registration Number
- NCT02090244
- Locations
- 🇸🇪
Ryggkliniken, US Linköping, Linköping, Sweden
🇸🇪Ortopedkliniken, Kalmar, Sweden
12 Month Extension Study of the Effect of Teriparatide on Bone in People With Chronic Spinal Cord Injury (SCI)
- Conditions
- Interventions
- First Posted Date
- 2013-12-31
- Last Posted Date
- 2023-05-10
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 25
- Registration Number
- NCT02025179
- Locations
- 🇺🇸
Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
Efficacy of Teriparatide in Diabetic Inactive Charcot Neuroarthropathy of Foot
- Conditions
- Interventions
- First Posted Date
- 2013-12-30
- Last Posted Date
- 2021-06-30
- Target Recruit Count
- 20
- Registration Number
- NCT02023411
- Locations
- 🇮🇳
Deptt of Endocrinology, Chandigarh, India
🇮🇳PGIMER, Chandigarh, India
Clinical Comparison of Efficacy and Safety of Two Teriparatide Formulations: Osteofortil and Forteo
- Conditions
- Interventions
- First Posted Date
- 2013-09-19
- Last Posted Date
- 2014-01-22
- Lead Sponsor
- Bio Sidus SA
- Target Recruit Count
- 110
- Registration Number
- NCT01945788
- Locations
- 🇦🇷
Instituto de Investigaciones Metabolicas, Ciudad Autonoma de Buenos Aires, Argentina
An Open-label Study to Evaluate the Effect of Treatment With Romosozumab or Teriparatide in Postmenopausal Women
- Conditions
- Interventions
- First Posted Date
- 2013-02-21
- Last Posted Date
- 2022-11-29
- Lead Sponsor
- Amgen
- Target Recruit Count
- 436
- Registration Number
- NCT01796301
- Locations
- 🇬🇧
Research Site, Sidcup, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.